These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7624889)

  • 1. Thermolabile hemoglobin formation by 2-cyanaziridine derivatives.
    Isert B; Schulte S; Mengel K; Friedberg KD
    Toxicol Lett; 1995 Aug; 78(3):189-94. PubMed ID: 7624889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The binding of ciamexone to globin: its demonstration and some accompanying effects in rats.
    Isert B; Götz G; van der Trenck KT; Friedberg KD
    Toxicol Appl Pharmacol; 1987 Mar; 87(3):490-7. PubMed ID: 3564022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence on the formation of unstable haemoglobin by the immunomodulating 2-cyanaziridines azimexone and BM 41.332 in mice.
    Isert B; Mengel K; Bicker U; Friedberg KD
    J Immunopharmacol; 1985; 7(2):179-93. PubMed ID: 4031509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ciamexone on lymphocytic thyroiditis and insulin-dependent diabetes mellitus in the BB/Wor rat.
    Abend S; Cormier J; Appel MC; Lueprasitsakul W; Alex S; Mordes JP; Usadel KH; Handler ES; Rossini AA; Braverman LE
    Immunopharmacology; 1990; 19(3):163-8. PubMed ID: 2394579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunomodulating basic therapy of rheumatoid arthritis using ciamexone].
    Baerwald C; Goebel KM; Krause A; Heymanns J
    Schweiz Med Wochenschr; 1989 Dec; 119(49):1769-71. PubMed ID: 2533393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciamexone suppressed anti-islet ADCC of mononuclear cells and serum from type 1 (insulin-dependent) diabetic patients.
    Köhler E; Knospe S; Hahn HJ; Roemer KG; Diamantstein T
    Exp Clin Endocrinol; 1989 May; 93(2-3):143-6. PubMed ID: 2673806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of spontaneous insulin-dependent diabetes in BB rats by administration of ciamexone.
    Kiesel U; Maruta K; Treichel U; Bicker U; Kolb H
    J Immunopharmacol; 1986; 8(3):393-406. PubMed ID: 3760592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciamexone--a new highly selective immunosuppressive compound.
    Bicker U; Pahlke W
    J Immunopharmacol; 1985; 7(1):127-39. PubMed ID: 4008940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.
    Kahaly G; Lieb W; Müller-Forell W; Mainberger M; Beyer J; Vollmar J; Staiger C
    Acta Endocrinol (Copenh); 1990 Jan; 122(1):13-21. PubMed ID: 2305603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose responses for the formation of hemoglobin adducts and urinary metabolites in rats and mice exposed by inhalation to low concentrations of 1,3-[2,3-(14)C]-butadiene.
    Booth ED; Kilgour JD; Watson WP
    Chem Biol Interact; 2004 Mar; 147(2):213-32. PubMed ID: 15013822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunosuppressive agents in endocrine ophthalmopathy. Clinical and experimental studies using cyclosporin and ciamexone].
    Kahaly G
    Fortschr Med; 1990 Aug; 108(23):454. PubMed ID: 2210582
    [No Abstract]   [Full Text] [Related]  

  • 12. Ciamexone, a highly selective immunomodulator--a tool for autoimmune diseases?
    Bicker U; Usadel KH
    Klin Wochenschr; 1986 Dec; 64(24):1261-6. PubMed ID: 3493387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric modifiers of hemoglobin: 2-[4-[[(3,5-disubstituted anilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid derivatives that lower the oxygen affinity of hemoglobin in red cell suspensions, in whole blood, and in vivo in rats.
    Abraham DJ; Wireko FC; Randad RS; Poyart C; Kister J; Bohn B; Liard JF; Kunert MP
    Biochemistry; 1992 Sep; 31(38):9141-9. PubMed ID: 1390701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the immunomodulant 2-cyanaziridine derivative BM 41.332 on adjuvant arthritis in the rat.
    Bicker U
    Arzneimittelforschung; 1982; 32(7):746-52. PubMed ID: 6889876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and properties of hemoglobin modified with derivatives of pyridoxal.
    Benesch R; Benesch RE
    Methods Enzymol; 1981; 76():147-59. PubMed ID: 7329258
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of glycidol-hemoglobin adducts as biomarkers of exposure and in vivo dose.
    Honda H; Törnqvist M; Nishiyama N; Kasamatsu T
    Toxicol Appl Pharmacol; 2014 Mar; 275(3):213-20. PubMed ID: 24467927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multiple functions of hemoglobin.
    Giardina B; Messana I; Scatena R; Castagnola M
    Crit Rev Biochem Mol Biol; 1995; 30(3):165-96. PubMed ID: 7555018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Damage to erythrocytes caused by the interaction of nitrite-ions with hemoglobin].
    Starodubtseva MN; Ignatenko VA; Cherenkevich SN
    Biofizika; 1999; 44(6):1068-72. PubMed ID: 10707282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants.
    Liu Q; Zhang H; Zhou G; Xie S; Zou H; Yu Y; Li G; Sun D; Zhang G; Lu Y; Zhong Y
    Int J Pharm; 2010 Sep; 397(1-2):122-9. PubMed ID: 20650309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.